At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

If enacted, BINSA would give lawmakers the right to monitor and restrict American companies from signing biotech and pharma-focused deals with Chinese entities.

AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.

While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.

Contraline could become the first to commercialise a reversible male contraceptive drug, provided the treatment is successful in Phase III.

At ASCO 2026, oral abstract presenters highlighted new and exciting central nervous system (CNS) tumour treatments.

The FDA has accepted BMS' sNDA for Camzyos to treat adolescents aged 12 to under 18 years with symptomatic oHCM.

At ASCO 2026, Pfizer presented top line data for the Phase III TALAPRO-3 clinical trial, evaluating Talzenna combined with Xtandi.

Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.

AstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-naïve, high-risk NMIBC.

Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide, worldwide ...

Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline.